Phase 2/3 Study of ALK-001 in Geographic Atrophy
Public ClinicalTrials.gov record NCT03845582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.
Study identification
- NCT ID
- NCT03845582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 200 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2019 (Actual)
- Primary completion
- Jul 25, 2023 (Actual)
- Completion
- Jun 30, 2024 (Actual)
- Last update posted
- Nov 3, 2025
2019 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkeus Site | Phoenix | Arizona | 85053 | — |
| Alkeus Site | Beverly Hills | California | 90211 | — |
| Alkeus Site | Lakewood | Colorado | 80228 | — |
| Alkeus Site | Clearwater | Florida | 33761 | — |
| Alkeus Site | Fort Myers | Florida | 33912 | — |
| Alkeus Site | Gainesville | Florida | 32601 | — |
| Alkeus Site | Tampa | Florida | 33609 | — |
| Alkeus Site | Winter Haven | Florida | 33880 | — |
| Alkeus Site | Bloomington | Illinois | 61704 | — |
| Alkeus Site | Lexington | Kentucky | 40509 | — |
| Alkeus Site | Chevy Chase | Maryland | 20815 | — |
| Alkeus Site | Worcester | Massachusetts | 01605 | — |
| Alkeus Site | Grand Rapids | Michigan | 49546 | — |
| Alkeus Site | Edina | Minnesota | 55435 | — |
| Alkeus Site | Northfield | New Jersey | 08225 | — |
| Alkeus Site | Great Neck | New York | 11021 | — |
| Alkeus Site | Hauppauge | New York | 11788 | — |
| Alkeus Site | Cleveland | Ohio | 44122 | — |
| Alkeus Site | Ashland | Oregon | 97520 | — |
| Alkeus Site | Houston | Texas | 77025 | — |
| Alkeus Site-1 | San Antonio | Texas | 78240 | — |
| Alkeus Site-2 | San Antonio | Texas | 78240 | — |
| Alkeus Site | Fairfax | Virginia | 22031 | — |
| Alkeus Site | Silverdale | Washington | 98383 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03845582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03845582 live on ClinicalTrials.gov.